{"entity":{"id":"nct05884398","kind":"trial","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","aka":["LIBERTAS"],"tldr":"A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC is a phase 3 interventional study registered as NCT05884398 by Janssen Research & Development, LLC, with 420 participants enrolled, started 2023-08-31 and due to reach its primary completion in 2026-10-12. Interventions recorded: Apalutamide, Androgen-deprivation Therapy (ADT). Conditions listed: Metastatic Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05884398","url":"https://clinicaltrials.gov/study/NCT05884398"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mhspc"],"sections":[],"technologies":["androgen-deprivation"],"targets":[],"drugs":["apalutamide"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05884398","phase":"3","setting":"A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","sponsor":"Janssen Research & Development, LLC","started":"2023-08-31","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05884398/","neighbours":{"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"}],"drug":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}